Outcomes of allogeneic hematopoietic cell transplant for acute myeloid leukemia in adolescent patients.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
20
07
2019
accepted:
06
08
2019
revised:
30
07
2019
pubmed:
7
9
2019
medline:
22
6
2021
entrez:
7
9
2019
Statut:
ppublish
Résumé
Patients between 14 and 22 years old are underrepresented in both adult and pediatric studies. We analyzed the outcomes of 94 consecutive patients aged between 14 and 22 who underwent myeloablative matched related-donor transplant while in first or second complete remission. We studied the impact of disease type, remission status, ELN risk group, ABO mismatch, time from diagnosis to transplant, patient and donor age, conditioning type, stem cell source, and the year of transplant on transplant outcomes. The cumulative incidences of relapse, NRM, OS, and DFS at 5 years were 42%, 10%, 59%, and 48%, respectively. Absence of ABO mismatch and donor age > 20 were associated with better OS and DFS on univariate and multivariate analysis. The cumulative incidence of aGVHD and cGVHD were 18% and 44%, respectively. Donor age > 20 and peripheral blood stem cell source were significantly associated with higher incidence of cGVHD on univariate and multivariate analysis. Younger patient age was significantly associated with higher incidence of aGVHD. In this age group, the determinants of survival seem to be dependent on donor variables rather on the traditional disease and patient related variables. Relapse still a significant factor for transplant failure while NRM was low.
Identifiants
pubmed: 31488877
doi: 10.1038/s41409-019-0667-1
pii: 10.1038/s41409-019-0667-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
182-188Références
Morgan S, Davies S, Palmer S, Plaster M. Sex, drugs, and rock ‘n’ roll: caring for adolescents and young adults with cancer. J Clin Oncol. 2010;28:4825–30.
doi: 10.1200/JCO.2009.22.5474
pubmed: 20498401
pmcid: 20498401
Veal GJ, Hartford CM, Stewart CF. Clinical pharmacology in the adolescent oncology patient. J Clin Oncol. 2010;28:4790–9.
doi: 10.1200/JCO.2010.28.3473
pubmed: 20439647
pmcid: 20439647
Gramatges MM, Rabin KR. The adolescent and young adult with cancer: state of the art–acute leukemias. Curr Oncol Rep. 2013;15:317–24.
doi: 10.1007/s11912-013-0325-5
pubmed: 23757222
pmcid: 23757222
Treadgold CL, Kuperberg A. Been there, done that, wrote the blog: the choices and challenges of supporting adolescents and young adults with cancer. J Clin Oncol. 2010;28:4842–9.
doi: 10.1200/JCO.2009.23.0516
pubmed: 20351337
pmcid: 20351337
Butow P, Palmer S, Pai A, Goodenough B, Luckett T, King M. Review of adherence-related issues in adolescents and young adults with cancer. J Clin Oncol. 2010;28:4800–9.
doi: 10.1200/JCO.2009.22.2802
pubmed: 20212260
pmcid: 20212260
Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol. 2010;28:4831–41.
doi: 10.1200/JCO.2009.22.8312
pubmed: 20458029
pmcid: 20458029
Kent EE, Sender LS, Morris RA, Grigsby TJ, Montoya MJ, Ziogas A, et al. Multilevel socioeconomic effects on quality of life in adolescent and young adult survivors of leukemia and lymphoma. Qual Life Res. 2013;22:1339–51.
doi: 10.1007/s11136-012-0254-z
pubmed: 22922952
pmcid: 22922952
Pemmaraju N, Kantarjian H, Ravandi F, Nogueras-Gonzalez GM, Huang X, O’Brien S, et al. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clin Lymphoma Myeloma Leuk. 2016;4:213–22.
Wein S, Pery S, Zer A. Role of palliative care in adolescent and young adult oncology. J Clin Oncol. 2010;28:4819–24.
doi: 10.1200/JCO.2009.22.4543
pubmed: 20212259
pmcid: 20212259
Coccia PF, Pappo AS, Altman J, Bhatia S, Borinstein SC, Flynn J, et al. Adolescent and young adult oncology, version 2. J Natl Compr Canc Netw. 2014;12:21–32. quiz
doi: 10.6004/jnccn.2014.0004
pubmed: 24453290
pmcid: 24453290
Bleyer A, Budd T, Montello M. Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer. 2006;107:1645–55.
doi: 10.1002/cncr.22102
pubmed: 16906507
pmcid: 16906507
Bleyer A, Viny A, Barr R. Cancer in 15- to 29-year-olds by primary site. Oncologist. 2006;11:590–601.
doi: 10.1634/theoncologist.11-6-590
Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M. Age standardization of rates: a new WHO standard. 9. Geneva: World Health Organization; 2001. p. 10.
Barr RD, Ries LA, Lewis DR, Harlan LC, Keegan TH, Pollock BH, et al. Incidence and incidence trends of the most frequent cancers in adolescent and young adult Americans, including “nonmalignant/noninvasive” tumors. Cancer. 2016;122:1000–8.
doi: 10.1002/cncr.29867
pubmed: 26848808
pmcid: 26848808
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
Creutzig U, Zimmermann M, Reinhardt D, Rasche M, von Neuhoff C, Alpermann T, et al. Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. Cancer. 2016;122:3821–30.
doi: 10.1002/cncr.30220
pubmed: 27529519
pmcid: 27529519
Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24:103.
doi: 10.1038/nm.4439
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. New Engl J Med. 2016;374:2209–21.
doi: 10.1056/NEJMoa1516192
Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Engl J Med. 2013;368:2059–74.
doi: 10.1056/NEJMoa1301689
Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–5.
doi: 10.1182/blood-2005-09-3724
pubmed: 16455952
pmcid: 1895766
Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29:487–94.
doi: 10.1200/JCO.2010.30.1820
Tomizawa D, Watanabe T, Hanada R, Horibe K, Horikoshi Y, Iwamoto S, et al. Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols. Int J Hematol. 2015;102:318–26.
doi: 10.1007/s12185-015-1825-x
Canner J, Alonzo TA, Franklin J, Freyer DR, Gamis A, Gerbing RB, et al. Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children’s Oncology Group. Cancer. 2013;119:4162–9.
doi: 10.1002/cncr.28342
pubmed: 4398142
pmcid: 4398142
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.
Sullivan KM. Acute and chronic graft-versus-host disease in man. Int J Cell Cloning. 1986;4:42–93.
doi: 10.1002/stem.5530040710
pubmed: 2943828
pmcid: 2943828
Majhail NS, Brazauskas R, Hassebroek A, Bredeson CN, Hahn T, Hale GA, et al. Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia. Biol Blood Marrow Transplant. 2012;18:861–73.
doi: 10.1016/j.bbmt.2011.10.031
pubmed: 22040843
pmcid: 22040843
Weisdorf D, Hakke R, Blazar B, Miller W, McGlave P, Ramsay N, et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation. 1991;51:1197–203.
doi: 10.1097/00007890-199106000-00010
pubmed: 2048196
pmcid: 2048196
Saraceni F, Beohou E, Labopin M, Arcese W, Bonifazi F, Stepensky P, et al. Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. Am J Hematol. 2018;93:1211–9.
doi: 10.1002/ajh.25225
Saraceni F, Labopin M, Hamladji R-M, Mufti G, Socie G, Shimoni A, et al. Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. Oncotarget. 2018;9:3379.
doi: 10.18632/oncotarget.23273
pubmed: 29423053
pmcid: 29423053